Mankind Pharma approved selling its entire stake in Broadway Hospitality for ₹49 crore. The company also greenlit forming a wholly-owned R&D subsidiary in the Netherlands, planning up to Euro 5 million investment.
Mankind Pharma Divests Non-Core Asset, Establishes Netherlands R&D Hub
Mankind Pharma announced a strategic move to sell its 100% stake in Broadway Hospitality Services Private Limited for ₹49 crore. The company also approved the formation of a wholly-owned subsidiary in the Netherlands.
Reader Takeaway: Divesting hospitality assets streamlines business while Netherlands subsidiary signals focus on international R&D growth.
What just happened
Mankind Pharma's Board of Directors has approved the sale of its entire shareholding in Broadway Hospitality Services Private Limited to AKRK Projects LLP for ₹49 crore. This divestment is part of the company's strategy to exit non-core assets.
Additionally, the board has sanctioned the incorporation of a wholly-owned subsidiary in the Netherlands. This new entity will serve as a hub for Research and Development (R&D) assets and focus on niche therapy development.
Why this matters
The sale of Broadway Hospitality will bring in ₹49 crore and remove a non-core business from Mankind Pharma's portfolio. The investment in a Netherlands subsidiary signals a strategic shift towards strengthening international R&D capabilities and developing niche therapies, potentially driving future growth.
The backstory
Broadway Hospitality Services Private Limited, as of March 31, 2026, reported a turnover of ₹9.63 crore and total income of ₹9.90 crore, with a net worth of ₹38.99 crore. The decision to divest this entity reflects a broader trend among pharmaceutical companies to focus on their core competencies.
What changes now
Mankind Pharma will no longer own Broadway Hospitality, freeing up capital and management focus. The establishment of the Netherlands subsidiary is a forward-looking step, intended to bolster its R&D pipeline and explore new therapeutic areas globally. An investment of up to Euro 5 million is planned for this subsidiary.
Risks to watch
Potential risks include the successful integration and operational efficiency of the new Netherlands subsidiary, the allocation of capital for R&D, and achieving desired outcomes in niche therapy development. Delays in the divestment completion, which is expected within 90 days, could also be a factor.
Peer comparison
Many large pharmaceutical companies are increasingly looking at international locations for R&D to leverage specialized talent pools and favorable regulatory environments for specific research areas. Establishing R&D hubs in Europe is a common strategy for global pharmaceutical players seeking innovation.
Context metrics (time-bound)
The sale of Broadway Hospitality is valued at ₹49 crore. The Netherlands subsidiary is set to receive an investment of up to Euro 5 million. Broadway Hospitality's turnover was ₹9.63 crore as of March 31, 2026.